4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001778623-26-000005
SVP, General Counsel and Sec. sold 30,000 shares at an average $80.80 ($2,423,958)
- SVP, General Counsel and Sec. acquired 30,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Veness Adam M SVP, General Counsel and Sec. | 2026-06-17 | Option exercise 10b5-1 | +30,000 | $17.88 | $536,400 | 30,000 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-06-17 | Sale 10b5-1 | −16,771 | $80.34 | $1,347,382 | 13,229 | D |
| Veness Adam M SVP, General Counsel and Sec. | 2026-06-17 | Sale 10b5-1 | −13,229 | $81.38 | $1,076,576 | 0 | D |
| Derivatives | |||||||
| Veness Adam M SVP, General Counsel and Sec. | 2026-06-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 80,000 | D | ||
| Open-market sales · 30,000 sh · avg $80.80 · $2,423,958 | |||||||
Loading xslF345X06/ownership.xml…